Ownership Summary
A total of 9 institutions have reported a stake in ProMIS Neurosciences Inc. (NASDAQ:PMN) as of December 2025, according to recent 13F filings with the SEC.
- ProMIS Neurosciences saw its institutional ownership percentage fell to 17.1% in December 2025 from 640.7% in September 2025.
- The company experienced a nan% quarterly change in institutional shares held, alongside a decrease of 52.63% in total owners annually.
- Of these 9 institutional investors, 9 increased their holdings in ProMIS Neurosciences, while 0 of them reduced positions, and 0 investors maintained their exposure.
- This class of investors increased its holdings in ProMIS Neurosciences to 264.55K shares for the 13F-cycle ending December 2025, up by 264.55K shares quarter on quarter, and down 9.48Mn shares year over year.
- The top institutional stake in ProMIS Neurosciences as of December 31, 2025 belongs to Ally Bridge Group (NY) LLC, which owns 249.34K shares, or 16.09% of the company.
- Among the most significant buyers of ProMIS Neurosciences during December 2025 were Ally Bridge Group (NY) LLC (249.34K), SPHERA FUNDS MANAGEMENT LTD. (11.81K), UBS Group AG (1.45K), Disciplined Equity Management, Inc. (1.00K), OSAIC HOLDINGS, INC. (360).
- The top 9 institutional holders of ProMIS Neurosciences for the quarter ending December 2025 included Ally Bridge Group (NY) LLC (249.34K), SPHERA FUNDS MANAGEMENT LTD. (11.81K), UBS Group AG (1.45K), Disciplined Equity Management, Inc. (1.00K), OSAIC HOLDINGS, INC. (360), Federation des caisses Desjardins du Quebec (330), ROYAL BANK OF CANADA (218), TD Waterhouse Canada Inc. (25), Tower Research Capital LLC (TRC) (20).